Xiaoyan Lin

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu et al. · Journal of Clinical Oncology · 2016 · 976 citations

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 625 citations

Hepatology, Medicine, Pathology +6

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 488 citations

Oncology, Clinical Trials, Chemotherapy-naive Patients +9

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 387 citations

Oncology, Metronomic Therapy, Nasopharyngeal Cancer +7